AbCellera R&D spend
AbCellera Biologics Inc. · ABCL (NASDAQ) · Vancouver, BC · Pharmaceuticals
Latest R&D (CAD)
$261.1M
Period ended 2025-12-31
Revenue (CAD)
$105.0M
248.7% of revenue · scale $165.6M
R&D by fiscal period
2025
$261.1M
2024
$229.1M
2023
$237.1M
2022
$140.4M
2021
$77.8M
2020
$39.4M
2019
$13.4M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $261,149,576 | $105,013,918 | $186,829,000 USD | 10-K | SEC EDGAR |
| 2024-12-31 | $229,111,378 | $39,495,443 | $167,259,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $237,085,603 | $51,322,342 | $175,658,000 USD | 10-K | SEC EDGAR |
| 2022-12-31 | $140,382,943 | $631,682,251 | $107,879,000 USD | 10-K | SEC EDGAR |
| 2021-12-31 | $77,794,717 | $470,316,961 | $62,062,000 USD | 10-K | SEC EDGAR |
| 2020-12-31 | $39,430,710 | $312,777,433 | $29,393,000 USD | 10-K | SEC EDGAR |
| 2019-12-31 | $13,418,940 | $15,407,963 | $10,113,000 USD | 10-K | SEC EDGAR |